TCRT Alaunos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TCRT

Price (delayed)

$1.3

Market cap

$20.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$14.75M

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 ...

Highlights
Alaunos Therapeutics's debt has plunged by 100% from the previous quarter and by 100% YoY
The company's quick ratio rose by 42% YoY and by 22% QoQ
The gross profit has dropped by 100% year-on-year and by 67% since the previous quarter
The revenue has plunged by 100% YoY and by 67% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ziopharm.com
Peers: OMER OMGA

Key stats

What are the main financial stats of TCRT
Market
Shares outstanding
16.01M
Market cap
$20.82M
Enterprise value
$14.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.31
Price to sales (P/S)
4,158.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,950.84
Earnings
Revenue
$5,000
EBIT
-$33.22M
EBITDA
-$30.62M
Free cash flow
-$28.8M
Per share
EPS
-$2.2
Free cash flow per share
-$1.8
Book value per share
$0.39
Revenue per share
$0
TBVPS
$0.52
Balance sheet
Total assets
$8.26M
Total liabilities
$1.96M
Debt
$0
Equity
$6.31M
Working capital
$6.31M
Liquidity
Debt to equity
0
Current ratio
4.22
Quick ratio
3.1
Net debt/EBITDA
0.2
Margins
EBITDA margin
-612,360%
Gross margin
100%
Net margin
-702,800%
Operating margin
-685,340%
Efficiency
Return on assets
-134.8%
Return on equity
-197%
Return on invested capital
-735.9%
Return on capital employed
-526.7%
Return on sales
-664,380%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TCRT stock price

How has the Alaunos Therapeutics stock price performed over time
Intraday
-4.41%
1 week
-1.52%
1 month
-28.57%
1 year
120.34%
YTD
1,738.76%
QTD
-28.18%

Financial performance

How have Alaunos Therapeutics's revenue and profit performed over time
Revenue
$5,000
Gross profit
$5,000
Operating income
-$34.27M
Net income
-$35.14M
Gross margin
100%
Net margin
-702,800%
The operating margin has plunged by 194% from the previous quarter
Alaunos Therapeutics's net margin has plunged by 189% from the previous quarter
The gross profit has dropped by 100% year-on-year and by 67% since the previous quarter
The revenue has plunged by 100% YoY and by 67% from the previous quarter

Growth

What is Alaunos Therapeutics's growth rate over time

Valuation

What is Alaunos Therapeutics stock price valuation
P/E
N/A
P/B
3.31
P/S
4,158.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,950.84
Alaunos Therapeutics's EPS has increased by 16% YoY and by 11% from the previous quarter
TCRT's equity has shrunk by 84% YoY and by 55% QoQ
The price to book (P/B) is 43% lower than the 5-year quarterly average of 5.8 and 15% lower than the last 4 quarters average of 3.9
The price to sales (P/S) is 197% higher than the last 4 quarters average of 1398.4
The revenue has plunged by 100% YoY and by 67% from the previous quarter

Efficiency

How efficient is Alaunos Therapeutics business performance
Alaunos Therapeutics's ROS has plunged by 196% from the previous quarter
The ROIC has shrunk by 188% YoY and by 37% QoQ
The company's return on assets has shrunk by 160% YoY and by 49% QoQ
The return on equity has dropped by 109% year-on-year and by 40% since the previous quarter

Dividends

What is TCRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TCRT.

Financial health

How did Alaunos Therapeutics financials performed over time
The total liabilities has plunged by 93% YoY and by 65% from the previous quarter
Alaunos Therapeutics's current ratio has soared by 89% YoY and by 53% from the previous quarter
Alaunos Therapeutics's debt is 100% less than its equity
The debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
Alaunos Therapeutics's debt has plunged by 100% from the previous quarter and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.